Treatment of Opioid Use Disorders in Pregnancy

Substance Use Screening and Reproductive Education and Counseling for Substance Using Women of Child-bearing Age: Online training from the Providers’ Clinical Support System for Medication-Assisted Treatment and the American Society of Addiction Medicine. Reviews the importance of screening for substance use during prenatal care and reproductive education and counseling content that can be integrated into substance treatment. http://pcssmat.org/substance-use-screening-and-reproductive-education-and-counseling-for-substance-using-women-of-child-bearing-age-asam/

American Congress of Obstetricians and Gynecologists (ACOG), Committee on Health Care for Underserved Women and the American Society of Addiction Medication (ASAM): Committee Opinion, Opioid Abuse, Dependence and Addiction in Pregnancy. Opioid use in pregnancy is not uncommon, and the use of illicit opioids during pregnancy is associated with an increased risk of adverse outcomes. It is the Committee’s opinion that the current standard of care for pregnant women with opioid dependence is referral for opioid-assisted therapy with methadone, but emerging evidence suggests that buprenorphine also should also be considered. http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Opioid-Abuse-Dependence-and-Addiction-in-Pregnancy

World Health Organization: Guidelines for Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder. They have been developed in response to requests from organizations, institutions and individuals for technical guidance on the identification and management of alcohol and other substance use and substance use disorders in pregnant women, with the target of healthy outcomes for both pregnant and their fetus or infant. http://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/

Treatment Improvement Protocol (TIP) 51: Substance Abuse Treatment, Addressing the Specific Needs of Women. Assists treatment providers in offering treatment to adult women with substance use disorders. Reviews gender-specific research and best practices, such as common patterns of initiation of substance use among women and specific treatment issues and strategies. http://store.samhsa.gov/product/TIP-51-Substance-Abuse-Treatment-Addressing-the-Specific-Needs-of-Women/SMA14-4426

American Congress of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice: Committee Opinion, Marijuana Use During Pregnancy and Lactation. This article describes the ACOG Committee Opinion to discontinue use of medical or recreational marijuana during pregnancy and while breastfeeding. http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Marijuana-Use-During-Pregnancy-and-Lactation

Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. Includes information on considerations for the treatment of alcohol use disorders in pregnancy. Provides guidance for the use of medication-assisted treatment for alcoholism and alcohol abuse in clinical practice. Summarizes approved medications and discusses screening and patient assessment, treatment planning, and patient monitoring. http://store.samhsa.gov/shin/content//SMA15-4907/SMA15-4907.pdf (PDF 507 KB)

The American Congress of Obstetricians and Gynecologists (ACOG) Toolkit on State Legislation: Pregnant Women & Prescription Drug Abuse, Dependence and Addiction. This toolkit provides talking points and policy recommendations from ACOG for state legislators and other policy organizations that are addressing pregnant women and prescription opioid use during pregnancy. http://www.acog.org/-/media/Departments/Government-Relations-and-Outreach/NASToolkit.pdf (PDF 287 KB)